Bruker (BRKRP) Q2 2026 earnings call transcript

I would now like to hand the call over to Joe Koska, Director of Investor Relations. Please go ahead. Good morning. I would like to welcome everyone to Burger Corporation's 2nd Quarter, 2026 earnings conference call. My name is Joe Koska, and I am the Director of Burger Investor Relations. Joining me on today's call are our President and CEO, Frank Laukeen, and our EVP and CFO, Gerald Herman.

In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events and Presentations section of Burger's Investor Relations website. During today's call, we will be highlighting non-GAP financial information.

Reconciliations of our non-GAP to GAP financial measures are included in our earnings release and are posted on our website at ir. brooker. com.

Before we begin, I would like to reference Brooker's Safe Harbor Statement, which is shown on slide two of the presentation.

During this conference call, we will or may make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to our recent acquisitions, geopolitical risks, wars or blockades, market demand, tariffs, currency exchange rates, competitive dynamics or supply chains. The company's actual results may differ materially from such statements.

Factors that might cause such differences include, but are not limited to, those discussed in today's earnings release and in our Form 10K for the period ending December 31st, 2025, as updated by our other SEC filings, which are available on our website and on the SEC's website. Also, please note that the following information is based on current business conditions and on our outlook as of today, August 4th, 2026.

We do not intend to update our forward-looking statements based on new information, future events, or for other reasons, except as may be required by law, prior to the release of our third quarter, 2026 financial results expected in early November, 2026. You should not rely on these forward-looking statements as necessarily representing our reviews or outlook as of any date after today.

We will begin today's call with Frank providing an overview of our business progress. Gerald will then cover the financials for the second quarter of 2026 in more detail and comment on our full year 2026 financial outlook. Now, I'd like to turn the call over to Brooker CEO, Frank Loughton.

Thanks, Joe. Good morning, everyone. And thank you for joining us on today's second quarter, 2026 earnings call. We are pleased that Brooker has returned to organic revenue growth in the second quarter and that our focus on cost reduction and profitability improvements resulted in solid margin expansion and non-GAP EPS growth.

Demand for our differentiated products and solutions improved further as our scientific instrument segment achieved 10% organic bookings growth year over year, a fourth consecutive quarter with a scientific instrument spoke to bill ratio above 1.0.

Organic bookings in BioPharma grew more than 20% in the second quarter driven by demand for our NMR, X-ray and mass spectrometry solutions.

In our academic and medical academic medical research business, bookings in Europe and China were up strongly. However, US academic orders still remained weak. In Q2, we saw notable Q2 order strength in our deep tech semiconductor tools and energy research technologies with both at over 50% organic order growth here over year. In semiconductor metrology, we sell robust and innovative metrology equipment for chip manufacturers, with significant demand increases for high bandwidth memory and advanced packaging driven by AI scaling.

In energy research, we provide unique tools and modules for fusion energy development and high energy physics research. These proprietary deep tech capabilities, which also include our security detection systems, are valuable to have in the portfolio as life science research demand recovers gradually. These deep tech tools tend to have a longer delivery times, in some cases of nine to 24 months, determined by facility readiness, for example, for a new logic or memory chip wafer fabs, or for large-scale fusion development projects.

As a result, some of our strong deep tech bookings will benefit our Q4 and then 2027 and even the outer years.

We are continuing to take costs out to drive margin expansion expansion and double-digit EPS growth this year and also again in 2027. We have made good progress in the second quarter, realizing more cumulative cost reductions and we are well on track for our stated goal of delivering 140 million of annualized cost savings in 2026. I would like to thank our teams for their very important efforts in this area.

Effective as of July 1st of this year, Brucker has adopted a new operating structure that combines our Biospin, Deltonics, and optics division into a new Brucker Biosystems group, led by group president, Jurgen Srega. The newly merged Biosystems group addresses the growing need for scientific integration in the post-genomic era, which combines complementary life science research workflows into more comprehensive disease biology insights.

Across post-genomic drug discovery, multi-omics and applied markets, our customers connect structural, molecular, and cellular information to understand complex systems biology or advanced materials research. The Biosystems group brings together NMR mass spectrometry, FTIR, Raman, preclinical automation software, and applications expertise in any of these areas for connected workflows from research to quality control.

Examples include metabolomics, RNA characterization, or protein analysis, where NMR and mass spectrometry provide important complementary insights, or as another example in battery research development and battery life cycle QC, where NMR and FTIR characterize electrolytes, electrodes, and chemistry.

In addition, Brucker microbiology and infection diagnostics, which we sometimes abbreviate as BIMIT, previously a division within the Cali group, has now been established as a group under the leadership of Dr. Rothkung Push. This BIMIT group has a fast-growing microbiology and infection diagnostics portfolio from microbicrobial identification, molecular diagnostics, hospital hygiene to emerging antimicrobial resistance testing, and next generation sequencing for sepsis and reflex testing.

This modified group structure aligns group of more closely with markets and our customers. By organizing around connected workflows, we strengthen group level agility and our ability to prioritize investments that deliver innovation with the most impact.

Following these changes, Brucker now operates in four groups, Brucker Biosystems, Brucker Nano, BIMIT, or Brucker Microbiology and Infection Diagnostics, and Brucker Energy and Supercon Technologies, or BEST. This new structure is expected to drive an additional 20 million of cost reductions in fiscal year 27.

All right, on to the quarter. Let's turn to slide four now for the P&L performance of the second quarter. Our Q226 reported revenues of 839 million increased 5.2 percent year over year with organic growth of 2.8 percent, or 3.4 percent organic growth, excluding tariff refunds in the second quarter.

The revenue contribution from M&A was 1.5 percent, and constant exchange rate or CER growth was 4.3 percent, and the 0.9 percent FX revenue tailwind was actually 50 bits lower than originally expected.

BSI segment revenues were up 2.3 percent organically while best achieved organic revenue growth of 8.9 percent net of intercompany eliminations.

Our second quarter, 26 non-gap growth and operating margins were 52.1 and 14.1 percent, respectively, both up significantly year over year, albeit in comparison to a weak second quarter 25. And including a net US tariff refund benefit that Gerald will describe in a moment.

Our second quarter 26 diluted non-gap EPS was 49 cents, up 53 percent from 32 cents in the second quarter of 25.

Moving to slide 5, H126 revenues increased by 3.9 percent to 1.6 billion, first half organic revenue was still the decline of 0.8 percent, consisting of a 1.4 percent organic decline in scientific instruments and 6.1 percent organic growth at best, net of intercompany eliminations. Our first half 26 non-gap growth margin, operating margin and EPS were all up year over year and their performance is summarized on slide 5.

Gerald will go into more detail on the drivers shortly. These turns to slide 6 and 7, where we highlight the first half 26 performance of our three scientific instruments group and of best, all in constant currency and year over year basis.

In the first half of 26, the Biasmin Group Group revenue was $393 million, down-mid single, down-mid single digits for percentage year over year. Biasmin saw strong revenue growth in hospital or clinical and biopharma, offset by weakness in China, Hakagav, food testing and automation. An MR-preclinical and preclinical imaging had robust order growth, both up-double digits in the first half year over year.

For the first half of 26, KALIC Group revenue of $627 million increased in the mid-single digits percentage driven by mass spectrometry, including the TOF work acquisition. KALIC saw strength in biopharma, security detection and European Hakagav, partially offset by weaker revenues in the US.

First half revenue growth in molecular diagnostics was solid, while microbiology was roughly flat. Please turn to slide 7 now. First half 2026, Brooklyn Nano revenue was $507 million, with a low single digits percentage decline.

Manosaw weakness in Akagav and industrial markets, while weakness in US Akagav funding, continued to impact spatial biology. This was largely offset by robust strength in semiconductor metrology due to AI-driven orders for memory and advanced packaging metrology tools.

Finally, the first half of 26 best revenues were up 6%, net-off intercompany eliminations, with strong growth in the superconductor business, and solid revenue growth at research instruments, or R. I. In the first half, R. I. secured very strong, multi-year orders for fusion energy and high energy physics to the technology. So I'll come back to that in a moment.

So moving to slide 8 and 9, on slide 8 we highlight our semiconductor metrology nanotools, which are not clearly moving the needle for broker.

In, I won't go through the technical details, but invite you to read those at your convenience. The first half 26 organic order growth was greater than 30%, and the first half 26 organic revenue growth was greater than 15%, obviously somewhat lagging behind order growth. And this business is very profitable. It has about a 30% e-bit margin.

Longer lead times in this business, which can be 9 to 24 months, can result in revenue lagging order growth by several quarters.

If you go to slide 9, we touch on our other deep tech areas, our security detection on the left, and energy research on the right. And those two businesses also seeing considerable strength. The first half detection orders and revenue were both up approximately 20% year over year. Whereas, as I just mentioned, our first half research instruments, our energy research, our orders were up well over 100% year over year.

In general, for perspective, keep in mind that broker in our orders tend to lag. Our revenues tend to lag the order trends by a couple of quarters.

And for these deep tech areas that I just mentioned, many of them will begin to help our revenue and P&L in Q4 of this year, and then very much into 27 and into the outer years. So in summary, in the second quarter, we achieved solid orders in many life signs and markets, and we achieved very strong order growth in our so-called deep tech tools.

We made further meaningful progress on our cost action, setting us up for continued margin expansion and ETS growth in fiscal year 26. And we are proactively taking additional cost out steps that are expected to add additional P&L benefits next year.

So with that, let me turn the call over to our CFO, Gerald Herman. We will review Brookers Q2 and fiscal year 26 outlook in more detail. Gerald.

Thank you, Frank, and thank you everyone for joining us today. And please provide more detail on Brooker's second quarter and first half, 2026 financial performance starting on slide 11.

In the second quarter of 2026, our results came in at the low end of our expectations on the top line, but meaningfully ahead of expectations on margins in ETS. Our top line results in the second quarter of 26 were unfavorably impacted by U. S. tariff refunds and a stronger U. S. dollar, which translated into less tailwind on revenue, in total approximately 110 basis points.

U. S. tariff refunds reduced our organic revenue growth from 3.4 percent to 2.8 percent, but strengthened our profitability in the quarter, adding around 200 basis points to the second quarter, 26 operating margins year over year. Net U. S. tariffs contributed about 6 cents to EPS in the second quarter. Most importantly, we also saw the accumulating impact of our cost-saving actions accelerate in the quarter, together with favorable mix and volume.

In the second quarter, 26 Brookers reported revenue increased 5.2 percent to 838.5 million dollars, reflecting a pivot to organic growth in the quarter of 2.8 percent for 3.4 percent year over year, excluding U. S. tariff refunds.

Acquisitions contributed 1.5 percent to our top line, while foreign exchange was a 0.9 percent tailwind, resulting in constant exchange rate for revenue growth of 4.3 percent year over year.

Geographically and on a year over year organic basis in the second quarter of 26, our Americas and European revenues both grew approximately 10 percent, while Asia-Pacific revenue declined in the low double digits percentage, including a low double digit decline of revenue in China. For our AMIA region, revenue was down low single digit percentage.

BSI organic revenue grew 2.3 percent in the second quarter of 26, with low single digit organic growth in Caled and Brooker Nano, partially offset 5 flat revenue performance in Biospin.

BSI systems revenue was roughly flat, and BSI aftermarket revenues were up mid-single digits organically year over year. Our BSI segment order book performance was up organically a solid 10 percent year over year, driven by greater than 50 percent growth in semi and greater than 20 percent growth in biopharma, partially offset by declines in U. S. ACAGOV and food safety.

Second quarter 26 non-gap gross margin increased 350 basis points to 52.1 percent. Non-gap operating margin was 14.1 percent of 510 basis points, driven by our cost-saving actions, positive net U. S. tariff impact and favorable volume mix, partially offset by foreign currency headwinds as shown on the slide. On a non-gap basis, second quarter 26 diluted EPS was 49 cents, up 53 percent, 53 percent rather from the 32 cents in the second quarter of 25, or a non-gap effective tax rate was 25 percent compared to 23.6 percent in the second quarter of 25.

On a gap basis, we reported a diluted loss per share of 41 cents, compared to gap EPS of five cents in the second quarter of 25. Our second quarter 26 gap results include a non-cash goodwill impairment charges of $135 million related to our automation and spatial biology businesses which continue to experience operating losses. Weighted average diluted shares outstanding in the second quarter of 2026, 452.8 million, an increase of 1.1 million shares from the second quarter of 2025.

Slide 12 shows Bruckers' performance for the first half of 2026, which has similar drivers to the second quarter. Turning to slide 13, in the second quarter of 2026, our operating cash flow improved $50 million year over year, driven by improved profitability and the timing of tax and vendor payments in the quarter. Pre-cash flow improved approximately $43 million on a year of a year basis. On stronger EBITDA in the second quarter of 2026, our net leverage ratio is now 2.8 times as of June 30, 2026. Turning now to slide 15, our fiscal year 2026 financial update outlook rather has been updated for foreign currency and effective tax rates only.

We now expect the foreign exchange tailwind to revenues of 0.5%, rather than 1.5% previously, resulting in reported revenue of $3.54 to $3.57 billion and representing reported growth of 3% to 4% compared to fiscal year 25. Organic revenue growth of 1% to 2% year over year, which is unchanged and acquisitions are expected to contribute 1.5% to growth also unchanged.

We continue to expect non-gap operating margin expansion of 250 to 300 basis points year over year, largely driven by our cost-saving actions. On the bottom line, we continue to expect to non-gap EPS for fiscal year 26 in a range of 210 to 215 or non-gap EPS growth of 15 to 17% compared to fiscal year 25, all unchanged. As lower headwinds from foreign exchange are broadly offset by higher or higher effective tax rate. Other guidance assumptions are listed on the slide.

Our fiscal year 2026 ranges have been updated for foreign currency rates as of June 30, 2026. Now some color on the third quarter of 26. We expect approximately $20 million of previously planned third quarter revenue to shift into the fourth quarter, driven by semiconductor customer delivery requirements. This results in Q3 organic revenue to be roughly flat to up slightly year over year.

On operating margins and EPS in the third quarter, we now expect a slight sequential decrease due to the $20 million semi-revenue shift from the third to the fourth quarter, and the six-cent net US tariff EPS benefit previously expected to come into the third quarter being pulled into the second quarter. On a positive note, for the fourth quarter of 2026, we now expect meaningful sequential and year-over-year increases in organic revenue growth, operating margin, and EPS due to significantly higher volume and favorable mix in the fourth quarter.

To wrap up, Q226 was another solid-booking squatter for Brueger, giving us further confidence in the gradual market recovery in several key markets and geographies. Our cost-saving actions are well on track, positioning us well for significant margin and profitability improvement in fiscal year 26, and we're driving towards further significant margin improvement in double-digit EPS growth also in 2027.

With that, I'd like to turn the call over back to Joe. Thank you very much.

Thanks, Gerald. We will now begin the Q&A portion of the call. As a reminder, to allow everyone time for questions, we ask that you limit yourself to one question and one follow-up operator.

All right, Puneet is, Gerald. So, on with respect to the first question, with respect to the tariff refunds, as you can guess, right, some of those tariff elements were charged to individual customers and that resulted in the contra-revenue element, which is considered in our press release and the materials we provided. With respect to EPS, we've also indicated that that generated roughly 200 basis points of margin expansion in the quarter for the second quarter. As far as the second half goes, we've already factored that or baked that into our earlier guide numbers. We had just actually assumed that it would be more likely recovered in the third and the fourth quarter is not in the second quarter.

So, we had a slightly earlier pull forward of that into the second quarter. But overall, that's already been baked into our original guidance model.

But just maybe one quick one on Semi. You're pointing to 50% order growth there, correct me if I'm wrong. But in terms of mean the visibility into this and the timing of delivery, maybe Frank, could you double-click? Obviously, this is an end market that is fairly actionable right now, just given the AI demand. What sort of sustainability that you're hearing from the customer end? Because obviously, these are somewhat separated from the leading AI companies that are driving that demand. So, maybe just could you elaborate a bit on the timing of the installs and conversion into revenue?

Yeah. I know the odors are remarkable for the first half and even more so in Q2. Of course, there'll be some fluctuations. But if anything, it seems to be accelerating as one would expect, probably. We think and from what we read about others that are more deeply in semi-conductor lithography or metrology, we think this is very sustainable this year and next. And then I think the debate is whether it's sustainable at that pace in 28 and beyond. People just don't know yet. But I would think the visibility of the sector for the next six quarters plus seems excellent.

That's not necessarily our own data. That's, you know, the general would be read from the industry. It is correct that many of these orders, as wonderful as they are, and they're absolutely fantastic. They usually have an even longer delivery times than an average, you know, an amount or a mess back. So, that can easily be three to sometimes, you know, six to eight quarters. Visibility is very good because those customers are very, they're almost like clockwork, right? And they know when they need it for a new waiver fab and so on. So, good visibility. But, you know, a little bit of a delayed gratification as more of some of that comes in in Q4. As Cheryl said, I think we'll have a very strong Q4 and then quite a bit of this goes into a next year in terms of revenue and PLL help and even into 28.

So, great sustainability, great visibility, slightly longer lead times. Got it.

Yeah, Mike. Thank you. So, other than about the combined effect of the of tariff refunds on revenue, which was, as you can see, with 60 bibs, and there is an additional 50 bibs effect from the currency tailwind actually being about 50 bibs lower than had been expected because currency rates changed. That'll become more pronounced in Q3. In Q3, that currency tailwind is on the revenues line is turning into a currency headwind. So, in Q3, that takes out about, it's not organic, but it takes out about 15 million in revenue independent of the revenue shift that Gerald had explained. But back to Q2 to your question. So, that combined effect was about 110 bibs of growth rate.

Still on the light side, on the revenues and on the organic revenues.

Thanks. Yeah, in terms of the, I mean, I mentioned in my prepared remarks on the third quarter, we are expecting some shift of revenue, particularly related to semi-strainters, just noting good strong orders in some of the revenue because of customer timing is moving to the fourth quarter. In addition, we, as I mentioned earlier, we did have a shift to what we expected from a tariff perspective over the third quarter to the second. So, we have slight, we think, from a margin perspective, we think this is likely going to be somewhat down from what we initially expected. And on the revenue line, we think we're going to be sort of flat to slightly up from an organic perspective in the third quarter.

Then, of course, we have a strong expected fourth quarter, significant growth there. There's a bunch of factors related to that. There's the push out I just described in semi- there's, we have a much stronger expectation around, we have an ultra high field coming into the fourth quarter, we have a number of mixed improvements that are much better, in that we have a much higher volume. And as I think you know, we get to a much better story in terms of our overall EPS growth in the fourth quarter. It's, it's shaping up to be a larger fourth quarter than we had expected, likely in around the billion dollar range. We've done this level of revenue growth in the past and the fourth quarter.

So, I think we, we just can execute to those levels. And that's our expectation at the moment.

Let's, let's start in the reverse order on the contractions. We're, we're well on track. We're north of $140 million. Frank mentioned the, the adoption of a new operating structure for Breaker and that's going to contribute some more additional savings beyond the $140 million we were planning for in, in 2026. That'll mostly hit in 2027, but still some. So we're well on track with, I would say a strong cost saving actions, even going forward beyond what we've already delivered. By the way, just from a cost savings perspective, we have delivered about 30 million in cost saving actions in the second quarter. So we're kind of right on track to where we expect it to be. With respect to the other questions, let's sort of take one, one at a time here.

I think our cadence with respect to the third quarter is just now shifted a little bit further into the fourth. As I said earlier, we have a strong set up in the fourth quarter, typically, even seasonally for Breaker and it appears they're going to have another one of those as we march into the fourth quarter of 26. The mixed story, we are going to get some and continue to get some pricing benefit from adjustments we made in 2025 into 26, including in the fourth quarter. The biggest piece, I'd say, for the fourth quarter performance is really going to be about volume.

With the scale that we will deliver in the fourth quarter, I think the volume piece is going to be much more important, actually, than just the mixed elements. But we do expect better mixed with respect to some, or also high field, and some of our other key businesses are going to perform more strongly in the fourth quarter based on what we see at this stage. I think, Ticot, so you're operating margin question.

If you even look at our slide 15, so if we haven't been clear enough, yeah, that continues to be based. Our guidance continues to be based on operating margin up to 150 to 300 bits reported, including a 50-bits headwind, and we'll detail a little bit on our slide 15 on the outlook, so that is unchanged.

And then on the cog side, Gerald, just inflationary memory tips, tungsten, et cetera.

Yeah, that seems to be, I mean, from an energy cost perspective, we've already baked that into the guide earlier. We're not seeing at least at this stage any significant pressure there. At this point, we are having some supply chain challenges around componentry, mostly in electronic side. But at this stage, we're pretty comfortable that that's already been baked in to our current guide.

And then, so we're seeing the encouraging NIH outlays, but they did not yet translate into significant two orders. We will observe what's happening in Q3, and of course, the Q3 budget flush, which seems to be underway, could for us also mean decent Q4, US, ECAGOV bookings, but we'll see. In Q2 already, the ECAGOV orders outside of the US, and particularly in the EU was up more than 10%, and in China, the orders were up more than 20% for ECAGOV in Q2. So remember, China was down on revenue, but then on orders, it was up more than 20% in ECAGOV. So that's that six months delay that you usually see at Frucker.

So yeah, QAGOV, which, you know, I think that really supports the strength of our ASMS mass back introduction, so the new things we can do with our NMRs, and of course our, you know, even our other spatial biology and how the tools are so that the portfolio, and I think it's spot on, I think the innovation will have major impact if we only had a little bit more US funding, but maybe that's coming, and where we have funding, it really, it has a big impact. So that bodes well for ECAGOV competitiveness and market shares gains, except it's starting right now in Europe and in APAC and China in particular. Thank you.

Q4 should have a nice single-digit organic growth rate, so it's a little bit of a rollercoaster with Q2 growth and Q4 organic growth and Q1 and Q3. Q1 what we've been aiming for and what's in our guidance, namely the organic revenue growth of 1 to 2%, which is a transition year admittedly because somebody comes from a year of 25 where we were declining organically for all the factors that you know. Whether Q4, the Q4 growth rate is then what an indicative of our 27 growth rate is too early to say. So give us another, give us a bit more time to see how bookings are opposite in Q3 and yes also in Q4 and then we'll be able to comment on that.

We generally believe of course in a further growth acceleration in 27 organic growth acceleration in 27 compared to 26, but we cannot quantify that at this time.

I don't think anything changed, Gerald was just talking about sequential. What happened is that we had assumed that we would get the tariff refunds maybe rate ably over Q2, Q3, Q4 and remarkably they came in rather quickly and mostly in June. So that's why our margins, that's why we pointed it out in Q2, our operating margins and our EPS had a greater benefit than we had expected from the tariff refunds coming in faster. We'll still have it sequentially Q2 in a good way. We overshot a little bit because some primarily because of these margins, these tariff refunds that really came in the last half of June. Quite honestly faster than we had expected. We thought the government would slow walk them.

They did not.

So you mean sequentially? Yeah. Were they down sequentially? No. No. They were sequentially.

We're scrambling for the numbers, but they were up.

1.02 to 1.04 or something like that. And the percentage of that, a lot of that is in our backlog now. But of course we also get some ongoing orders. I don't have a number right now. More than 50% for sure. But I don't have an exact number. Probably 2-thirds. But again, sorry. I do not have a... You've dumped us twice. We do not have exact numbers for both of your questions.

We will, however, when we call you back because we just don't have it at our fingertips. All right. That's a bucket list to stump you twice, Frank.

Wow. Luke, you're on a roll. More questions.

Oh, yeah. So on the... And just sticking on the guide here, as you guys think about the pickup and the business, but like from a demand perspective, what needs to get better? Is it all an academic side? Are you seeing continued momentum on the pharma? You know, anything there from a geography or M market that needs to actually improve for you to realize that back at the work you guide? Well, quite honestly, almost everything is pretty good now. Applied markets, so food and food analysis a little weak, but that's small for us anyway.

And US-Aka-Gav clearly is the one outlier, even with US-Aka-Gav, even in state week, we'll take a growth step up next year. And if US-Aka-Gav came back, at least in a modest way, then, you know, obviously we take a bigger growth step up next year. So more and more areas, biopharma has been great in the last two or three quarters. And again, in Q2, so pharma, biopharma, the tools that we sell into that, Tim's Omni's, Tim's subsystems, and a Mars spatial biology x-ray. It's really all quite good. But then what people sometimes call these idiosyncratic growth drivers, because they're not what we call them deep technology, because they're not all life science, but they're absolutely terrific.

However, you know, with this delayed gratification of them typically having nine, sometimes longer, not nine months or longer, delivery times, and that's driven by the customers not by our capacity.

Yeah.

And then, how do you view the sustainability of both of those businesses in terms of demand as we look into 2027, especially on the security side? On the security side, that was better than expected, but not, not, not hugely better. We expected strong security detection orders, but probably not greater than 20%. So it was incrementally better than what we had expected.

It seems very, we have a very good product line there and differentiated product plus security and defense concerns are not evading. So that looks very sustainable. I think that business for as far as I can see or anybody can see who would expect good growth trends there and with good margins in security detection that started, you know, whatever, a couple of years ago, and it's just been getting stronger. It was incrementally stronger than expected, but partly baked in. A lot of these orders are four things that you deliver to an airport sometime middle of next year. So it doesn't all go into Q2, Q3, Q4. And energy research that greatly exceeded in terms of timings and amount that greatly exceeded what we had expected.

It's well over 100%. At that level, at that high growth rate, it's not sustainable, but that business is very sustainable because a lot of some of these orders are literally for 27, 28, and some going to 29, so they'll have very good continuing revenue growth in the foreseeable future. But they've been batting, I don't know, they've been batting 800 or something, instead of the usual batting 400 to use baseball terminology. It's just done really, really well.

And their order and order success rate and win rate has been ahead of their own expectations and we're delighted.

Maybe just walk through what you're seeing, you know, across the businesses in that region. Thank you. And what region was that I didn't catch it? Europe grew 10%. So just maybe unpack that performance. Thank you. I believe it was healthy on NMR, on other biospin tools as well, EPR and pre-clinical imaging. It was healthy on the mass back offerings.

I don't have it, but for all the other divisions. It was a bit of very healthy also on that, sorry, on molecular diagnostics. Our LDTech business is just doing great. And they just keep growing and then placing instruments ahead of business plan last year. They thought that might settle a little bit. It hasn't had first half booking certain first half placements in molecular diagnostics. The LDTech business was ahead. Well, it had a business plan. And, you know, that then boats very well as the consumables pulled through that builds on that larger installed base.

Those were some of the highlights.

Yeah. And I just had biopharma with solid as well in that, in the quarter in Europe.

What portion of the portfolio falls into that bucket of six plus quarters when it comes to acceptance and just hitting the trying to get my hands around on pie charts, et cetera, within that business?

Okay. I Dan, thinking for a moment. So the deep tech portfolio is maybe all together is around 15% of our portfolio. Now, I cannot break out how much of that would have three or four quarters delivery time versus six and longer that I can't break out readily. But the deep tech portfolio with a longer delivery time of, let's say, three, three to six quarters is about 15% of our portfolio. And that does not include in this case, we have not 15%. We have not included super looked at instruments and systems and modules rather than superconducting wires. If you, yes. So 15% is deep tech semiconductor metrology, security detection, energy research.

But in this case, I did not bundle the supercon solutions into that. That, of course, they have, you know, they get these five or seven year framework contracts that has a very different rhythm. But about 15%, I think, is the question that you're 15%, that's probably what you're looking for.

And of course, there is even block eight and all right. So it's manageable because we've taken so many proactive steps in recent years. First of all, at our factories and final test sites that use a lot of helium, they really all have helium. Reliquification, liquid faction, sorry, it's the terminology. So we capture all of it and we liquefy all of it. And I think we're at 80, 90% that we liquefy.

In addition, many of our newer magnets for the customers and also for our deliveries and installations have considerably lower helium consumption. And we've offered now for some years, we and also some other third party vendors. Helium gas capture and recompression, repurification, liquefication, liquefaction solution. So more and more of the larger labs are equipped with that. So I'm not saying it's paying free, but it's been greatly mitigated. And I'd say at the overall financial level, it's not something we need to highlight. It's manageable.

When did they go a bit more into Caled first? The microbiology business flat year to date. Can you just give us an update on what you're seeing in Mali? Historically, that's been a pretty steady double digit grower. Are there any regional or kind of dynamics you would call out? Hi, Jack. So I, no, I don't think so. I think there's just also some quarterly fluctuations.

They ended up getting some very large deals that they'll expect to deliver in Q3 and Q4, for instance, in Latin America and some other places. So I think that's more of a fluctuation generally that instruments business tends to be maybe now made sometimes a single digit grower, but the aftermarket for that business tends to be in the double digit grower. So Anna, that's also our expectation for the year.

Okay. Well, we're not ready for 27 color or guidance. But yes, we very much intend to again grow our margins well above 100 bits next year as well from our 26 basis. And of course, we're looking for double digits, hopefully mid teams, EPS, non-GAP EPS growth next year as well. As we had said, and that won't end with 27, we're really on our goal is to drive back towards a 20% EBIT operating margin as quickly as possible. And then more gradually move up to, you know, to the low 20s in EBIT and mid 20s in EBIT top.

Yes.

So for the year, as you've seen, that's the FX part that we adjusted in our overall guidance. It's now a half percent tailwind and it used to be one and a half percent tailwind. And the biggest effect of that is in Q3 and in Q4. So that's not organic. So maybe it shouldn't be a concern, but just saying Q4 growth. Yeah. Mostly the 20 million in deliveries that we did, I think our shifting from that Gerald said, our shifting from Q3 to Q4. So almost all semi. That's simply when the sites are ready, when the customers are ready. And of course, it's a little different in the mix from what we had expected at the beginning of the year.

We're a little bit more semi-heavy and faster turning Akhagav or so in the U. S. So weaker than we had expected because money is coming out later. And the ultra high field that we are expecting in Q4 revenue, I mean, these things are never guaranteed because we have to install them. But I think our success ratio of delivery and then success on installations is greater than 80%. But don't get hung up on that either. The NMR business always has the ability to make it up. If one slides out, they'll try to put something else. So we're pretty comfortable with our strong Q4 guidance or implied guidance for Q4 at this point. I think that's simply what happens every year.

We try to smooth it out a little bit. And then during the year, some customer delays or sometimes technical delays come in. So I think we'll be cool and Q4 and Q4 should be a good quarter and Q3 should be okay. But sequentially not as strong as what we had expected.

I would like to turn the call back over to Joe Kafka for any closing remarks. Thank you for joining us today. Brooker's leadership team looks forward to meeting with you at an event or speaking with you directly during the third quarter. Feel free to reach out to me to arrange a follow-up. Have a good day.